Advanced Practice Providers & Life Sciences 2025
- Nurse practitioners (NPs) and physician assistants (PAs) are increasingly vital in prescribing and shaping patient care, prompting a meaningful shift in life sciences marketing.
- The 2024 MM+M Healthcare Marketers Trend Report indicates a surge in recognition of NPs and PAs, jumping from 4.8% in 2022 to 20.9% in 2023.
- with over 740,000 NPs and PAs in the U.S., their influence is undeniable.
Life sciences marketing is undergoing a profound transformation as nurse practitioners (nps) and physician assistants (PAs) ascend as primary prescribers, reshaping treatment landscapes. Pharmaceutical companies must swiftly adapt, recognizing the meaningful influence of these healthcare professionals. News Directory 3 observes a surge in attention toward NPs and PAs. With over 740,000 NPs and PAs in the U.S., and a majority actively prescribing, their impact is undeniable, shaping patient care across various specialties. To effectively engage these providers, life sciences brands should prioritize peer-driven education and tailored digital content. Are your strategies aligned with these evolving preferences? Discover what’s next for your brand in this dynamic healthcare surroundings.
Life Sciences marketing Adapts to the Rise of NPs and PAs
Updated June 02, 2025
Nurse practitioners (NPs) and physician assistants (PAs) are increasingly vital in prescribing and shaping patient care, prompting a meaningful shift in life sciences marketing. for years,pharmaceutical companies focused primarily on physicians. Though, NPs and PAs now represent a rapidly growing segment of prescribing healthcare providers.
The 2024 MM+M Healthcare Marketers Trend Report indicates a surge in recognition of NPs and PAs, jumping from 4.8% in 2022 to 20.9% in 2023. This underscores the necessity for brands to prioritize engagement with thes professionals to capitalize on a substantial market opportunity.
with over 740,000 NPs and PAs in the U.S., their influence is undeniable. Data reveals that 557,616 NPs and PAs are active prescribers, independently managing treatment plans. They write 37.2% of all U.S. prescriptions and see 47.7% of all U.S. patients,extending their reach across primary and specialty care,including cardiology,endocrinology,and dermatology.
These frontline providers prioritize patient education and accessibility, often working in community clinics, retail settings, and telehealth platforms. Their direct interactions significantly impact treatment adherence and long-term health outcomes. NPs and PAs manage chronic diseases, initiate new therapies, and provide crucial access to underserved populations.
Many life sciences marketing strategies still prioritize physicians, overlooking the prescribers who are actively making treatment decisions. This outdated approach misses a critical opportunity to connect with NPs and PAs effectively.
Research indicates that over 80% of NPs and PAs prefer peer-led education and digitally-engaged content, such as webinars and case studies.They seek actionable, evidence-based resources to enhance their treatment decisions, rather than promotional materials.
to effectively reach NPs and PAs, life sciences companies must align with their preferences for information consumption and peer engagement. Strategies should include peer-driven content, targeted digital education, and access to relevant networks.
Deb Nevins, chief marketing & strategy officer at POCN Group, emphasized the importance of evolving engagement strategies. She said brands that invest in tailored, data-driven approaches will achieve greater success and improve patient treatment and adherence.
The future of HCP engagement must include NPs and PAs. The question is—is your brand ready to evolve?
What’s next
Life sciences companies must adapt their marketing strategies to include NPs and PAs to drive treatment adoption and improve patient outcomes. Brands that evolve their engagement strategies will see stronger success in the changing healthcare landscape.